TY - JOUR
TI - Immunogenicity and side-effects of the inactivated hepatitis A vaccine in periodic fever, aphthous stomatitis, pharyngitis, and adenitis patients
AU - Maritsi, D.N.
AU - Syrmou, A.
AU - Vartzelis, G.
AU - Diamantopoulos, S.
AU - Tsolia, M.N.
JO - Pediatrics International
PY - 2019
VL - 61
TODO - 1
SP - 104-106
PB - Blackwell Publishing Inc.
SN - 1328-8067, 1442-200X
TODO - 10.1111/ped.13719
TODO - hepatitis A vaccine;  immunoglobulin G;  hepatitis A vaccine;  immunoglobulin G, Article;  child;  clinical article;  cohort analysis;  controlled study;  drug efficacy;  drug safety;  drug tolerability;  female;  fever;  Greece;  hepatitis A;  human;  humoral immunity;  injection site induration;  malaise;  male;  observational study;  pediatrics;  PFAPA syndrome;  priority journal;  prospective study;  seroconversion;  vaccination;  vaccine immunogenicity;  blood;  case control study;  hereditary periodic fever;  immunology;  preschool child, Case-Control Studies;  Child;  Child, Preschool;  Female;  Hepatitis A Vaccines;  Hereditary Autoinflammatory Diseases;  Humans;  Immunity, Humoral;  Immunoglobulin G;  Male;  Prospective Studies
TODO - The aim of this study was to compare the immunogenicity and side-effects of hepatitis A virus (HAV) vaccination between periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) patients and healthy controls who have not been previously exposed to HAV. A prospective observational study was carried out of 28 PFAPA patients and 76 controls who received two doses of the vaccine. Immunogenicity was expressed as seroconversion and seroprotection rates; mean HAV-immunoglobulin G concentration was measured at 0, 1, 7 and 18 months. Side-effects were defined as incidence of adverse events and the effect of vaccination on PFAPA symptoms. All participants were seronegative and seroconverted at 1 month. One month after primary vaccination, 92.9% of PFAPA patients and 77.6% of the controls attained seroprotection, while the rates increased to 100% and 96.1%, respectively, 1 month after the second dose. Seroprotection rates remained adequate 1 year after completion of vaccination. In conclusion, two doses of the inactivated HAV vaccine are well-tolerated and effective in children with PFAPA. © 2019 Japan Pediatric Society
ER -